5-fluoro-uracil · Oncology 5-fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cell death.
Capecitabine tablets · Oncology Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.
177Lu-PMSA-617 · Oncology 177Lu-PMSA-617 is a radioligand therapy that delivers lutetium-177 radiation directly to prostate cancer cells expressing PSMA, causing targeted cell death.
AC regimen · Oncology AC regimen is a chemotherapy combination of doxorubicin (Adriamycin) and cyclophosphamide that damages cancer cell DNA to inhibit tumor growth.
CHEMOTHERAPY then HORMONOTHERAPY · Oncology A sequential treatment regimen that first uses chemotherapy to reduce tumor burden, followed by hormone therapy to suppress hormone-dependent cancer cell growth.
FOLFOX4s · Oncology FOLFOX4s is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
Fulvestrant Prefilled Syringe · Oncology Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors in hormone receptor-positive breast cancer cells.
HIPEC · Oncology HIPEC is a hyperthermic intraperitoneal chemotherapy delivery system that circulates heated chemotherapy drugs directly into the abdominal cavity during surgery to treat peritoneal cancers.
IV Chemotherapy (Regimen 1) · Oncology IV Chemotherapy Regimen 1 is a combination chemotherapy treatment that kills rapidly dividing cancer cells through DNA damage and cell cycle disruption.
L-folinic · Oncology L-folinic acid (leucovorin) is a reduced form of folic acid that enhances the activity of fluorouracil-based chemotherapy by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the cofactor.
mFolfox6 or capecitabine · Oncology capecitabine is a prodrug that is converted into 5-fluorouracil, which is then incorporated into DNA and RNA, interfering with cancer cell replication.
Nivolumab Injection · Oncology Nivolumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.
Reduced dose intensity of IO · Oncology Reduced dose intensity of immunotherapy (IO) aims to maintain anti-tumor efficacy while decreasing treatment-related toxicity through lower or less frequent dosing schedules.
Phase 2 pipeline
AMG102 · Oncology AMG102 is a recombinant human tumor necrosis factor (TNF) receptor fusion protein.
DNA intercalators · Oncology DNA intercalators insert themselves between DNA base pairs to disrupt DNA replication and transcription, leading to cancer cell death.